BIP Alliance LLC purchased a new position in Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,542 shares of the company's stock, valued at approximately $368,000.
Several other institutional investors have also made changes to their positions in the stock. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson in the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson during the fourth quarter valued at about $29,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth about $32,000. Conquis Financial LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth about $33,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $36,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities research analysts have issued reports on JNJ shares. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Barclays cut their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.
View Our Latest Research Report on Johnson & Johnson
Insider Buying and Selling
In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This trade represents a 25.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.
Johnson & Johnson Price Performance
JNJ stock traded down $0.68 during midday trading on Thursday, reaching $152.50. 7,528,277 shares of the company's stock traded hands, compared to its average volume of 7,976,459. The company has a 50-day simple moving average of $155.67 and a two-hundred day simple moving average of $153.79. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market cap of $366.93 billion, a price-to-earnings ratio of 22.93, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. On average, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.41%. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is 57.84%.
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
